Company history

• Founded on over two decades of research, the Company was formed in 2014 and listed on the UK stock market.
• From the outset, we constructed a library of bacteria isolated from healthy human samples, which now stands at more than 4,000 strains.
• We have built a drug discovery platform, known as MicroRx, which has shown the ability to rapidly identify bacteria from our library that have therapeutically relevant effects.
• Starting in late 2014, the Company has initiated 15 live biotherapeutic programmes across a broad range of diseases.
• The Company has received FDA Orphan Designation for its programmes in paediatric Crohn’s disease and paediatric Ulcerative Colitis.
• We have developed humanised preclinical models, which since 2015 have allowed us to test our products in more disease-relevant settings and improve their translational potential.
• The Company commenced a clinical study of Blautix in patients with IBS in 2015. This trial has now been completed and successfully reached its primary objective.
• In November 2015, 4D announced that it had developed a live biotherapeutic which shows efficacy in preclinical models of cancer.
• The Company has established its own development and manufacturing facility, completed in 2016, which is dedicated to the production of our live biotherapeutics.
• In August 2016, we commenced dosing in patients of our live biotherapeutic for paediatric Crohn’s disease.